腹腔镜与机器人妇科肿瘤手术的死亡率:系统综述与Meta分析
该系统综述与Meta分析纳入65项研究共39183例患者,评估妇科肿瘤微创手术(腹腔镜与机器人)30天内手术死亡率。总死亡率为1:381(95%CI,1:306-1:474)。早期宫颈癌根治性子宫切除术死亡率为1:2049,子宫内膜癌伴淋巴结清扫为1:195,卵巢癌为1:685。腹腔镜与机器人两种入路在任何类型妇科肿瘤手术中死亡率无显著差异(RR 1.12,95%CI 0.35-3.49)。
要点
- 妇科肿瘤微创手术总体30天内死亡率为1:381(95%CI,1:306-1:474)。
- 早期宫颈癌根治性子宫切除术死亡率为1:2049(95%CI,1:356-1:11832)。
- 子宫内膜癌伴淋巴结清扫死亡率为1:195(95%CI,1:109-1:349)。
核心结论
- 妇科肿瘤微创手术总体手术死亡率为1:381(95%CI,1:306-1:474)。
- 早期宫颈癌患者死亡率为1:2049(95%CI,1:356-1:11832),子宫内膜癌伴淋巴结清扫患者为1:195(95%CI,1:109-1:349),卵巢癌患者为1:685(95%CI,1:44-1:10971)。
- 对于接受任何类型妇科肿瘤手术的患者,微创手术入路类型(腹腔镜与机器人)之间无差异。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Scopus、Web of Science和Cochrane数据库近10年文献。
- 纳入报告微创手术(腹腔镜与机器人)任何原因30天内手术死亡率的妇科肿瘤研究,排除未报告微创手术死亡率或包含良性妇科疾病的研究。
- 共纳入65项研究、39183例患者;采用逆方差法计算合并死亡率,采用Mantel-Haenszel法计算相对风险及95%CI。
主要发现
- 总手术死亡率为1:381(95%CI,1:306-1:474)。
- 39183例患者中38619例接受任何类型子宫切除术,死亡率为1:379(95%CI,1:304-1:472)。
- 腹腔镜入路死亡率为1:281(95%CI,1:169-1:469),机器人入路死亡率为1:476(95%CI,1:365-1:620)。
- 3369例早期宫颈癌接受根治性子宫切除术患者死亡率为1:2049(95%CI,1:356-1:11832);3501例子宫内膜癌接受子宫切除术伴淋巴结清扫患者死亡率为1:195(95%CI,1:109-1:349);418例卵巢癌接受微创手术患者死亡率为1:685(95%CI,1:44-1:10971)。
- 11项研究共4037例患者比较任何类型妇科肿瘤手术死亡率,腹腔镜为1:626,机器人为1:716,相对风险为1.12(95%CI,0.35-3.49)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To review early operative mortality (<30 days) for minimally invasive surgery (MIS), laparoscopic and robotic, in gynecologic oncology. DATA SOURCES: An electronic-based search was performed in PubMed, Embase, Scopus, Web of Science, and Cochrane Database in the last 10 years. METHODS OF STUDY SELECTION: All MIS studies in gynecologic oncology reporting operative mortality from any cause (within 30 days) were included. Studies were excluded if mortality was not reported for MIS or included benign gynecology. TABULATION, INTEGRATION, AND RESULTS: Meta-analysis was applied to calculate pooled mortality rates using the inverse-variance method. The relative risks and their corresponding 95% confidence intervals (CIs) were calculated using the Mantel-Haenszel method. Sixty-five studies were included (39 183 patients) for an operative mortality of 1:381 (95% CI, 1:306-1:474). Studies were subselected and analyzed by procedures, malignancy, and surgical approach. Of 39 183 patients, 38 619 underwent any type of hysterectomy for a mortality of 1:379 (95% CI, 1:304-1:472). The mortality was 1:281 (95% CI, 1:169-1:469) for a laparoscopic approach and 1:476 (95% CI, 1:365-1:620) for a robotic approach. There were 3369 patients with early cervical cancer undergoing radical hysterectomy with a mortality of 1:2049 (95% CI, 1:356-1:11 832). There were 3501 patients with endometrial cancer undergoing hysterectomy with lymph node dissection with a mortality of 1:195 (95% CI, 1:109-1:349). There were 418 patients with ovarian cancer undergoing MIS procedures with a mortality of 1 in 685 (95% CI, 1:44-1:10971). Eleven studies with 4037 patients compared mortality of gynecologic oncology surgery of any type (laparoscopic [1:626] vs robotic [1:716] for a relative risk of 1.12 [95% CI, 0.35-3.49]). CONCLUSION: The overall operative mortality for minimally invasive surgery in gynecologic oncology is 1 in 381 (95% CI, 1:306-1:474). For patients with early cervical cancer, it is 1:2049 (95% CI, 1:356-1: 11832), for endometrial cancer with node dissection it is 1:195 (95% CI, 1:109-1:349), and for ovarian cancer it is 1 in 685 (95% CI, 1:44-1:10 971). There is no difference between the type of MIS approach for patients undergoing any type of gynecologic oncology surgery.
引用
- Behbehani S, Suarez-Salvador E, Buras M, et al. Mortality Rates in Laparoscopic and Robotic Gynecologic Oncology Surgery: A Systemic Review and Meta-analysis. J Minim Invasive Gynecol. 2019. PMID: 31279137. doi:10.1016/j.jmig.2019.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。